ClinicalTrials.gg
CompletedNCT01292135Updated Jul 24, 2014Results posted

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

A Phase 1 interventional study of PCI-32765 in B-cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-24.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
49th of 83
33 · median 44
Started
2011
the only one that year
Phase 1
17 of 83
1 open now
Registered
4th of 83
by date
Lead sponsor
10 of 83
Pharmacyclics LLC.

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 49th largest by enrollment, is the only one that started in 2011, is one of 17 in phase 1, and was the 4th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to establish the safety of orally administered PCI-32765 in combination with fludarabine/cyclophosphamide/rituximab (FCR) and bendamustine/rituximab (BR) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma(SLL).

Read the detailed description

This is a Phase 1b, open-label, parallel-group, nonrandomized, multicenter study of PCI 32765 420 mg once daily oral (PO) administration in combination with 2 different chemotherapy regimens in subjects with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

03

Conditions studied

  • B-cell Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Lymphoma, B-Cell
  • Leukemia, Lymphoid
  • Leukemia, B-Cell
  • Bruton's Tyrosine Kinase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed CLL or SLL and satisfying at least 1 of the following criteria for requiring treatment:

    • Progressive splenomegaly and/or lymphadenopathy identified by physical examination or radiographic studies
    • Anemia (\<11 g/dL) or thrombocytopenia (\<100,000/μL) due to bone marrow involvement
    • Presence of unintentional weight loss > 10% over the preceding 6 months
    • Grade 2 or 3 fatigue
    • Fevers > 100.5° or night sweats for > 2 weeks without evidence of infection
    • Progressive lymphocytosis with an increase of > 50% over a 2 month period or an anticipated doubling time of \< 6 months
  2. 1 to 3 prior treatment regimens for CLL/SLL
  3. performance status of ≤ 1
  4. ≥ 18 years of age
  5. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
  6. Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (in accordance with national and local subject privacy regulations)

Exclusion criteria

Exclusion Criteria:

  1. Any chemotherapy, therapeutic antineoplastic antibodies (not including radio- or toxin immunoconjugates), radiation therapy, or experimental antineoplastic therapy within 4 weeks of first dose of study drug
  2. Radio- or toxin-conjugated antibody therapy within 10 weeks of first dose of study drug
  3. Concomitant use of medicines known to cause or torsades de pointes
  4. Transformed lymphoma or Richter's transformation Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 PO, or put the study outcomes at undue risk
  5. Any of the following laboratory abnormalities: oAbsolute (ANC) \< 1000 cells/mm3 (1.0 x 109/L) oPlatelet count \< 50,000/mm3 (50 x 109/L) oSerum (AST/SGOT) or alanine transaminase (ALT/SGPT) ≥ 3.0 x (ULN) oCreatinine > 2.0 x ULN or \< 40 mL/min
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR)

    Drug: PCI-32765

  • Experimental
    PCI-32765 plus bendamustine/rituximab (BR)

    Drug: PCI-32765

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Prolonged Hematologic Toxicity Started in Cycle 1

    Time frame: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.

Secondary outcomes

  1. Incidence of Adverse Events Requiring Dose Delay or Discontinuation of Ibrutinib

    Time frame: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.

  2. Overall Incidence of Grade ≥3 Adverse Events (AEs) Per NCI CTCAE V4.0

    Time frame: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.

  3. Overall Incidence of Serious Adverse Events (SAEs)

    Time frame: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.

  4. Overall Response Rate (Complete Response [CR] + Complete Response With Incomplete Marrow Recovery [CRi] + Nodular Partial Response [nPR] + Partial Response [PR])

    Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. Assessment of response to treatment will be done every 2 cycles for the first 6 months and then every 3 months thereafter until disease progression or prior to the administration of a new anticancer therapy and at follow-up visits.

    Time frame: From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.

  5. Sustained Hematologic Improvement in Subjects With Neutropenia, Anemia, or Thrombocytopenia at Baseline

    Time frame: From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.

  6. Progression Free Survival Rate at 12 Months

    Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size.

    Time frame: From first dose of any study medication to 12 months after first dose to progressive disease or death or the last clinical assessment before receiving new anticancer therapy or loss to follow-up, whichever occured the earliest.

07

Results

Posted Jul 24, 2014

Participant flow

Participant flow — Overall Study
MilestonePCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR)PCI-32765 Plus Bendamustine/Rituximab (BR)
Started330
Completed321
Not completed09

Outcome measures

PrimaryIncidence of Prolonged Hematologic Toxicity Started in Cycle 1
Time frame:
From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Reported as:
Number · Percentage of Participants
Incidence of Prolonged Hematologic Toxicity Started in Cycle 1
Percentage of ParticipantsPCI-32765 Plus Bendamustine/Rituximab (BR)PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)
Incidence of Prolonged Hematologic Toxicity Started in Cycle 10 (0 to 11.6)0 (NA to NA)
SecondaryIncidence of Adverse Events Requiring Dose Delay or Discontinuation of Ibrutinib
Time frame:
From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Reported as:
Number · Percentage of Participants
Incidence of Adverse Events Requiring Dose Delay or Discontinuation of Ibrutinib
Percentage of ParticipantsPCI-32765 Plus Bendamustine/Rituximab (BR)PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)
Incidence of Adverse Events Requiring Dose Delay or Discontinuation of Ibrutinib53.333.3
SecondaryOverall Incidence of Grade ≥3 Adverse Events (AEs) Per NCI CTCAE V4.0
Time frame:
From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Reported as:
Number · Percentage of Participants
Overall Incidence of Grade ≥3 Adverse Events (AEs) Per NCI CTCAE V4.0
Percentage of ParticipantsPCI-32765 Plus Bendamustine/Rituximab (BR)PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)
Overall Incidence of Grade ≥3 Adverse Events (AEs) Per NCI CTCAE V4.066.70
SecondaryOverall Incidence of Serious Adverse Events (SAEs)
Time frame:
From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Reported as:
Number · Percentage of Participants
Overall Incidence of Serious Adverse Events (SAEs)
Percentage of ParticipantsPCI-32765 Plus Bendamustine/Rituximab (BR)PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)
Overall Incidence of Serious Adverse Events (SAEs)2033.3
SecondaryOverall Response Rate (Complete Response [CR] + Complete Response With Incomplete Marrow Recovery [CRi] + Nodular Partial Response [nPR] + Partial Response [PR])

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. Assessment of response to treatment will be done every 2 cycles for the first 6 months and then every 3 months thereafter until disease progression or prior to the administration of a new anticancer therapy and at follow-up visits.

Time frame:
From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.
Reported as:
Number · Percentage of Participants
Overall Response Rate (Complete Response [CR] + Complete Response With Incomplete Marrow Recovery [CRi] + Nodular Partial Response [nPR] + Partial Response [PR])
Percentage of ParticipantsPCI-32765 Plus Bendamustine/Rituximab (BR)PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)
Overall Response Rate (Complete Response [CR] + Complete Response With Incomplete Marrow Recovery [CRi] + Nodular Partial Response [nPR] + Partial Response [PR])93.3 (77.9 to 99.2)100 (NA to NA)
SecondarySustained Hematologic Improvement in Subjects With Neutropenia, Anemia, or Thrombocytopenia at Baseline
Time frame:
From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.
Reported as:
Number · Percentage of Participants
Sustained Hematologic Improvement in Subjects With Neutropenia, Anemia, or Thrombocytopenia at Baseline
Percentage of ParticipantsPCI-32765 Plus Bendamustine/Rituximab (BR)PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)
Sustained Hematologic Improvement in Subjects With Neutropenia, Anemia, or Thrombocytopenia at Baseline76.2 (52.8 to 91.8)—
SecondaryProgression Free Survival Rate at 12 Months

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size.

Time frame:
From first dose of any study medication to 12 months after first dose to progressive disease or death or the last clinical assessment before receiving new anticancer therapy or loss to follow-up, whichever occured the earliest.
Reported as:
Number · Percentage of Participants
Progression Free Survival Rate at 12 Months
Percentage of ParticipantsPCI-32765 Plus Bendamustine/Rituximab (BR)PCI- 32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR)
Progression Free Survival Rate at 12 Months85.9 (66.7 to 94.5)100 (100 to 100)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCI-32765 Plus Bendamustine/Rituximab (BR)—6/30 (20%)30/30 (100%)
PCI-32765 Plus Fludarabine/ Cyclophosphamide/Rituximab (FCR)—1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventPCI-32765 Plus Bendamustine/Rituximab (BR)PCI-32765 Plus Fludarabine/ Cyclophosphamide/Rituximab (FCR)
GastritisGastrointestinal disorders0/301/3
Viral InfectionInfections and infestations0/301/3
Febrile neutropeniaBlood and lymphatic system disorders2/300/3
CellulitisInfections and infestations2/300/3
DehydrationMetabolism and nutrition disorders1/300/3
Tumour lysis syndromeMetabolism and nutrition disorders1/300/3
Most frequent other events
Showing 10 of 83
Most frequent other events
EventPCI-32765 Plus Bendamustine/Rituximab (BR)PCI-32765 Plus Fludarabine/ Cyclophosphamide/Rituximab (FCR)
HypocalcaemiaMetabolism and nutrition disorders3/303/3
DiarrhoeaGastrointestinal disorders21/301/3
ThrombocytopeniaBlood and lymphatic system disorders5/302/3
AnaemiaBlood and lymphatic system disorders2/302/3
NauseaGastrointestinal disorders20/302/3
HypomagnesaemiaMetabolism and nutrition disorders4/302/3
FatigueGeneral disorders14/300/3
NeutropeniaBlood and lymphatic system disorders12/301/3
Upper respiratory tract infectionInfections and infestations11/301/3
Dry mouthGastrointestinal disorders4/301/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR)PCI-32765 Plus Bendamustine/Rituximab (BR)Total
Mean56.3 ± 1.5361.3 ± 9.5860.8 ± 9.24
Age, Categorical
Age, Categorical(Participants)PCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR)PCI-32765 Plus Bendamustine/Rituximab (BR)Total
<=18 years000
Between 18 and 65 years31922
>=65 years01111
Sex: Female, Male
Sex: Female, Male(Participants)PCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR)PCI-32765 Plus Bendamustine/Rituximab (BR)Total
Female055
Male32528
Region of Enrollment
Region of Enrollment(participants)PCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR)PCI-32765 Plus Bendamustine/Rituximab (BR)Total
United States33033
08

Study locations

6 sites
  • Dana Farber Cancer Center
    Boston, Massachusetts 02115, United States
  • CLL Research and Treatment Program
    New Hyde Park, New York 11042, United States
  • Weill Medical College of Cornell University
    New York, New York 10065, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • MD Anderson
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 7;125(19):2915-22. doi: 10.1182/blood-2014-09-585869. Epub 2015 Mar 9. PubMed 25755291 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Nov 2012 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2011
First posted
Feb 9, 2011
Start
Feb 2011
Primary completionActual
Nov 2012
CompletionActual
May 2013
Results first posted
Jul 24, 2014
Last update
Jul 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01292135
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Feb 9, 2011
Start date
Feb 2011
Primary completion
Nov 2012
Completion
May 2013
Results posted
Jul 24, 2014
Last update
Jul 24, 2014

Study contacts

Thorsten Graef, MD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion